Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s traded shares stood at 4.1 million during the last session, with the company’s beta value hitting 0.62. At the close of trading, the stock’s price was $14.10, to imply an increase of 0.36% or $0.05 in intraday trading. The IOVA share’s 52-week high remains $18.33, putting it -30.0% down since that peak but still an impressive 77.23% since price per share fell to its 52-week low of $3.21. The company has a valuation of $3.94B, with an average of 6.78 million shares in intraday trading volume over the past 10 days and average of 10.44 million shares over the past 3 months.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
After registering a 0.36% upside in the last session, Iovance Biotherapeutics Inc (IOVA) has traded red over the past five days. The stock hit a weekly high of 15.90, jumping 0.36% in its intraday price action. The 5-day price performance for the stock is -5.56%, and -19.29% over 30 days. With these gigs, the year-to-date price performance is 73.43%. Short interest in Iovance Biotherapeutics Inc (NASDAQ:IOVA) saw shorts transact 46.71 million shares and set a 3.33 days time to cover.
Iovance Biotherapeutics Inc (IOVA) estimates and forecasts
Looking at statistics comparing Iovance Biotherapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Iovance Biotherapeutics Inc (IOVA) shares are 217.57% up over the last 6 months, with its year-to-date growth rate higher than industry average at 25.93% against 12.60%. Revenue is forecast to grow 16.00% this quarter before jumping 23.40% for the next one. The rating firms project that company’s revenue will grow 13,547.60% compared to the previous financial year.
Revenue forecast for the current quarter as set by 12 analysts is $2.07 million. Meanwhile, for the quarter ending Jun 2024, a total of 12 analyst(s) estimate revenue growth to $28.6 million.Earnings reports from the last fiscal year show that sales brought in $200k and $238k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 935.00% before jumping 11,916.80% in the following quarter.
IOVA Dividends
Iovance Biotherapeutics Inc has its next earnings report out between May 07 and May 13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Iovance Biotherapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Iovance Biotherapeutics Inc insiders hold 0.56% of total outstanding shares, with institutional holders owning 89.20% of the shares at 89.70% float percentage. In total, 89.20% institutions holds shares in the company, led by Vanguard Group Inc. As of Jun 29, 2023, the company held over 20.4 million shares (or 8.23% of shares), all amounting to roughly $143.58 million.
The next major institution holding the largest number of shares is Blackrock Inc. with 17.0 million shares, or about 6.86% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $119.69 million.
We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Iovance Biotherapeutics Inc (IOVA) shares. Going by data provided on Aug 30, 2023, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 8.87 million shares. This is just over 3.58% of the total shares, with a market valuation of $53.58 million. Data from the same date shows that the other fund manager holds a little less at 6.59 million, or 2.66% of the shares, all valued at about 46.39 million.
